Your browser doesn't support javascript.
loading
Development and validation of prediction models for fetal growth restriction and birthweight: an individual participant data meta-analysis.
Allotey, John; Archer, Lucinda; Coomar, Dyuti; Snell, Kym Ie; Smuk, Melanie; Oakey, Lucy; Haqnawaz, Sadia; Betrán, Ana Pilar; Chappell, Lucy C; Ganzevoort, Wessel; Gordijn, Sanne; Khalil, Asma; Mol, Ben W; Morris, Rachel K; Myers, Jenny; Papageorghiou, Aris T; Thilaganathan, Basky; Da Silva Costa, Fabricio; Facchinetti, Fabio; Coomarasamy, Arri; Ohkuchi, Akihide; Eskild, Anne; Arenas Ramírez, Javier; Galindo, Alberto; Herraiz, Ignacio; Prefumo, Federico; Saito, Shigeru; Sletner, Line; Cecatti, Jose Guilherme; Gabbay-Benziv, Rinat; Goffinet, Francois; Baschat, Ahmet A; Souza, Renato T; Mone, Fionnuala; Farrar, Diane; Heinonen, Seppo; Salvesen, Kjell Å; Smits, Luc Jm; Bhattacharya, Sohinee; Nagata, Chie; Takeda, Satoru; van Gelder, Marleen Mhj; Anggraini, Dewi; Yeo, SeonAe; West, Jane; Zamora, Javier; Mistry, Hema; Riley, Richard D; Thangaratinam, Shakila.
Afiliación
  • Allotey J; WHO Collaborating Centre for Global Women's Health, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
  • Archer L; Centre for Prognosis Research, School of Medicine, Keele University, Keele, UK.
  • Coomar D; WHO Collaborating Centre for Global Women's Health, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
  • Snell KI; Centre for Prognosis Research, School of Medicine, Keele University, Keele, UK.
  • Smuk M; Blizard Institute, Centre for Genomics and Child Health, Queen Mary University of London, London, UK.
  • Oakey L; WHO Collaborating Centre for Global Women's Health, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
  • Haqnawaz S; The Hildas, Dame Hilda Lloyd Network, WHO Collaborating Centre for Global Women's Health, University of Birmingham, Birmingham, UK.
  • Betrán AP; Department of Reproductive and Health Research, World Health Organization, Geneva, Switzerland.
  • Chappell LC; Department of Women and Children's Health, School of Life Course Sciences, King's College London, London, UK.
  • Ganzevoort W; Department of Obstetrics, Amsterdam UMC University of Amsterdam, Amsterdam, the Netherlands.
  • Gordijn S; Faculty of Medical Sciences, University Medical Center Groningen, Groningen, the Netherlands.
  • Khalil A; Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust and Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.
  • Mol BW; Department of Obstetrics and Gynaecology, Monash University, Monash Medical Centre, Clayton, Victoria, Australia.
  • Morris RK; Aberdeen Centre for Women's Health Research, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
  • Myers J; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • Papageorghiou AT; Maternal and Fetal Health Research Centre, Manchester Academic Health Science Centre, University of Manchester, Central Manchester NHS Trust, Manchester, UK.
  • Thilaganathan B; Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust and Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.
  • Da Silva Costa F; Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust and Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.
  • Facchinetti F; Tommy's National Centre for Maternity Improvement, Royal College of Obstetrics and Gynaecology, London, UK.
  • Coomarasamy A; Maternal Fetal Medicine Unit, Gold Coast University Hospital and School of Medicine, Griffith University, Gold Coast, Queensland, Australia.
  • Ohkuchi A; Mother-Infant Department, University of Modena and Reggio Emilia, Emilia-Romagna, Italy.
  • Eskild A; WHO Collaborating Centre for Global Women's Health, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
  • Arenas Ramírez J; Department of Obstetrics and Gynecology, Jichi Medical University School of Medicine, Shimotsuke-shi, Tochigi, Japan.
  • Galindo A; Akershus University Hospital, University of Oslo, Oslo, Norway.
  • Herraiz I; Hospital Universitario de Cabueñes, Gijón, Spain.
  • Prefumo F; Fetal Medicine Unit, Maternal and Child Health and Development Network (SAMID), Department of Obstetrics and Gynaecology, Hospital Universitario, Instituto de Investigación Hospital, Universidad Complutense de Madrid, Madrid, Spain.
  • Saito S; Department of Obstetrics and Gynaecology, Hospital Universitario, Madrid, Spain.
  • Sletner L; Department of Clinical and Experimental Sciences, University of Brescia, Italy.
  • Cecatti JG; Department Obstetrics and Gynecology, University of Toyama, Toyama, Japan.
  • Gabbay-Benziv R; Deptartment of Pediatric and Adolescents Medicine, Akershus University Hospital, Sykehusveien, Norway.
  • Goffinet F; Obstetric Unit, Department of Obstetrics and Gynecology, University of Campinas, Campinas, Sao Paulo, Brazil.
  • Baschat AA; Maternal Fetal Medicine Unit, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center Hadera, Affiliated to the Ruth and Bruce Rappaport School of Medicine, Technion, Haifa, Israel.
  • Souza RT; Maternité Port-Royal, AP-HP, APHP, Centre-Université de Paris, FHU PREMA, Paris, France.
  • Mone F; Université de Paris, INSERM U1153, Equipe de recherche en Epidémiologie Obstétricale, Périnatale et Pédiatrique (EPOPé), Centre de Recherche Epidémiologie et Biostatistique Sorbonne Paris Cité (CRESS), Paris, France.
  • Farrar D; Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, MD, USA.
  • Heinonen S; Obstetric Unit, Department of Obstetrics and Gynecology, University of Campinas, Campinas, Sao Paulo, Brazil.
  • Salvesen KÅ; Centre for Public Health, Queen's University, Belfast, UK.
  • Smits LJ; Bradford Institute for Health Research, Bradford, UK.
  • Bhattacharya S; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Nagata C; Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway.
  • Takeda S; Care and Public Health Research Institute, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • van Gelder MM; Aberdeen Centre for Women's Health Research, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
  • Anggraini D; Center for Postgraduate Education and Training, National Center for Child Health and Development, Tokyo, Japan.
  • Yeo S; Department of Obstetrics and Gynecology, Juntendo University, Tokyo, Japan.
  • West J; Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Zamora J; Faculty of Mathematics and Natural Sciences, Lambung Mangkurat University, South Kalimantan, Indonesia.
  • Mistry H; University of North Carolina at Chapel Hill, School of Nursing, NC, USA.
  • Riley RD; Bradford Institute for Health Research, Bradford, UK.
  • Thangaratinam S; WHO Collaborating Centre for Global Women's Health, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
Health Technol Assess ; 28(47): 1-119, 2024 Aug.
Article en En | MEDLINE | ID: mdl-39252507
ABSTRACT

Background:

Fetal growth restriction is associated with perinatal morbidity and mortality. Early identification of women having at-risk fetuses can reduce perinatal adverse outcomes.

Objectives:

To assess the predictive performance of existing models predicting fetal growth restriction and birthweight, and if needed, to develop and validate new multivariable models using individual participant data.

Design:

Individual participant data meta-analyses of cohorts in International Prediction of Pregnancy Complications network, decision curve analysis and health economics analysis.

Participants:

Pregnant women at booking. External validation of existing models (9 cohorts, 441,415 pregnancies); International Prediction of Pregnancy Complications model development and validation (4 cohorts, 237,228 pregnancies). Predictors Maternal clinical characteristics, biochemical and ultrasound markers. Primary

outcomes:

fetal growth restriction defined as birthweight <10th centile adjusted for gestational age and with stillbirth, neonatal death or delivery before 32 weeks' gestation birthweight.

Analysis:

First, we externally validated existing models using individual participant data meta-analysis. If needed, we developed and validated new International Prediction of Pregnancy Complications models using random-intercept regression models with backward elimination for variable selection and undertook internal-external cross-validation. We estimated the study-specific performance (c-statistic, calibration slope, calibration-in-the-large) for each model and pooled using random-effects meta-analysis. Heterogeneity was quantified using τ2 and 95% prediction intervals. We assessed the clinical utility of the fetal growth restriction model using decision curve analysis, and health economics analysis based on National Institute for Health and Care Excellence 2008 model.

Results:

Of the 119 published models, one birthweight model (Poon) could be validated. None reported fetal growth restriction using our definition. Across all cohorts, the Poon model had good summary calibration slope of 0.93 (95% confidence interval 0.90 to 0.96) with slight overfitting, and underpredicted birthweight by 90.4 g on average (95% confidence interval 37.9 g to 142.9 g). The newly developed International Prediction of Pregnancy Complications-fetal growth restriction model included maternal age, height, parity, smoking status, ethnicity, and any history of hypertension, pre-eclampsia, previous stillbirth or small for gestational age baby and gestational age at delivery. This allowed predictions conditional on a range of assumed gestational ages at delivery. The pooled apparent c-statistic and calibration were 0.96 (95% confidence interval 0.51 to 1.0), and 0.95 (95% confidence interval 0.67 to 1.23), respectively. The model showed positive net benefit for predicted probability thresholds between 1% and 90%. In addition to the predictors in the International Prediction of Pregnancy Complications-fetal growth restriction model, the International Prediction of Pregnancy Complications-birthweight model included maternal weight, history of diabetes and mode of conception. Average calibration slope across cohorts in the internal-external cross-validation was 1.00 (95% confidence interval 0.78 to 1.23) with no evidence of overfitting. Birthweight was underestimated by 9.7 g on average (95% confidence interval -154.3 g to 173.8 g).

Limitations:

We could not externally validate most of the published models due to variations in the definitions of outcomes. Internal-external cross-validation of our International Prediction of Pregnancy Complications-fetal growth restriction model was limited by the paucity of events in the included cohorts. The economic evaluation using the published National Institute for Health and Care Excellence 2008 model may not reflect current practice, and full economic evaluation was not possible due to paucity of data. Future work International Prediction of Pregnancy Complications models' performance needs to be assessed in routine practice, and their impact on decision-making and clinical outcomes needs evaluation.

Conclusion:

The International Prediction of Pregnancy Complications-fetal growth restriction and International Prediction of Pregnancy Complications-birthweight models accurately predict fetal growth restriction and birthweight for various assumed gestational ages at delivery. These can be used to stratify the risk status at booking, plan monitoring and management. Study registration This study is registered as PROSPERO CRD42019135045.

Funding:

This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref 17/148/07) and is published in full in Health Technology Assessment; Vol. 28, No. 14. See the NIHR Funding and Awards website for further award information.
One in ten babies is born small for their age. A third of such small babies are considered to be 'growth-restricted' as they have complications such as dying in the womb (stillbirth) or after birth (newborn death), cerebral palsy, or needing long stays in hospital. When growth restriction is suspected in fetuses, they are closely monitored and often delivered early to avoid complications. Hence, it is important that we identify growth-restricted babies early to plan care. Our goal was to provide personalised and accurate estimates of the mother's chances of having a growth-restricted baby and predict the baby's weight if delivered at various time points in pregnancy. To do so, first we tested how accurate existing risk calculators ('prediction models') were in predicting growth restriction and birthweight. We then developed new risk-calculators and studied their clinical and economic benefits. We did so by accessing the data from individual pregnant women and their babies in our large database library (International Prediction of Pregnancy Complications). Published risk-calculators had various definitions of growth restriction and none predicted the chances of having a growth-restricted baby using our definition. One predicted baby's birthweight. This risk-calculator performed well, but underpredicted the birthweight by up to 143 g. We developed two new risk-calculators to predict growth-restricted babies (International Prediction of Pregnancy Complications-fetal growth restriction) and birthweight (International Prediction of Pregnancy Complications-birthweight). Both calculators accurately predicted the chances of the baby being born with growth restriction, and its birthweight. The birthweight was underpredicted by <9.7 g. The calculators performed well in both mothers predicted to be low and high risk. Further research is needed to determine the impact of using these calculators in practice, and challenges to implementing them in practice. Both International Prediction of Pregnancy Complications-fetal growth restriction and International Prediction of Pregnancy Complications-birthweight risk calculators will inform healthcare professionals and empower parents make informed decisions on monitoring and timing of delivery.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Peso al Nacer / Retardo del Crecimiento Fetal Límite: Adult / Female / Humans / Newborn / Pregnancy Idioma: En Revista: Health Technol Assess Asunto de la revista: PESQUISA EM SERVICOS DE SAUDE / TECNOLOGIA MEDICA Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Peso al Nacer / Retardo del Crecimiento Fetal Límite: Adult / Female / Humans / Newborn / Pregnancy Idioma: En Revista: Health Technol Assess Asunto de la revista: PESQUISA EM SERVICOS DE SAUDE / TECNOLOGIA MEDICA Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Reino Unido